Sodium glucose cotransporter 2 inhibitors in the management of heart failure:Veni,Vidi,and Vici

作     者：Monika Bhandari Akshyaya Pradhan Pravesh Vishwakarma Abhishek Singh Rishi Sethi 

作者机构：Department of CardiologyKing Georg’s Medical UniversityLucknow 226003Uttar PradeshIndia 

出 版 物：《World Journal of Cardiology》 (世界心脏病学杂志（英文版）（电子版）)

年 卷 期：2024年第16卷第10期

页      面：550-563页

学科分类：083002[工学-环境工程] 0830[工学-环境科学与工程（可授工学、理学、农学学位）] 08[工学] 

主　　题：Heart failure with preserved ejection fraction Gliflozins Diuresis Natriuresis N terminal-pro brain natriuretic peptide Heart failure hospitalization 

摘      要：Heart failure(HF)is a chronic disease associated with high morbidity and mortality ***-angiotensin-aldosterone system blockers(including angiotensin receptor/neprilysin inhibitors),beta-blockers,and mineralocorticoid receptor blockers remain the mainstay of pharmacotherapy for HF with reduced ejection fraction(HFrEF).However,despite the use of guideline-directed medical therapy,the mortality from HFrEF remains *** with preserved ejection fraction(HFpEF)comprises approximately half of the total incident HF cases;however,unlike HFrEF,there are no proven therapies for this *** glucose cotransporter-2 inhibitors(SGLT-2is)represent a new class of pharmacological agents approved for diabetes mellitus(DM)that inhibit SGLT-2 receptors in the kidney.A serendipitous finding from seminal trials of SGLT-2is in DM was the significant improvement in renal and cardiovascular(CV)*** importantly,the improvement in HF hospitalization(HHF)in the CV outcomes trials of SGLT-2is was *** mechanisms have been proposed for the pleiotropic effects of SGLT-2is beyond their glycemic ***,as patients with HF were not included in any of these trials,it can be considered as a primary ***,two landmark studies of SGLT-2is in patients with HFrEF,namely,an empagliflozin outcome trial in patients with chronic HF and a reduced ejection fraction(EMPEROR-Reduced)and dapagliflozin and prevention of adverse outcomes in HF(DAPA-HF),demonstrated significant improvement in HHF and CV mortality regardless of the presence of *** impressive results pitchforked these drugs as class I indications in patients with HFrEF across major ***,empagliflozin outcome trial in patients with chronic HF with preserved ejection fraction(EMPEROR-Preserved)and dapagliflozin evaluation to improve the lives of patients with preserved ejection fraction HF(DELIVER)trials successively confirmed that SGLT-2is also benefit patients w